DelveInsight: One Year Anniversary!

  • Home Blog Delveinsight celebrating one year anniversary

DelveInsight: One Year Anniversary!

Feb 27, 2015

Inline image 1

Thanks to our great Clients, Partners, Colleagues, Family and Friends, we’re celebrating the completion of our first year in business.

Thanks for helping to make DelveInsight a success!!

Downloads

Article in PDF

Recent Articles
  1. Gilead’s TRODELVY Shows PFS Benefit in 1L Metastatic TNBC; Otsuka’s Sibeprenlimab Gets FDA Priori...
  2. Meet DelveInsight in BioEurope '16
  3. Business Cocktail
  4. Business Cocktail
  5. Metastatic Prostate Cancer-Pipeline Insights, 2014
pharma-news-for-incyte-gilead-archeus
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Incyte’s MONJUVI Combo Approved by FDA for Relapsed/Refractory Follicular Lymphoma; Gilead’s YEZTUGO Becomes First FDA-Approved HIV Prevention with 6-Month Protection; FDA Reviewing Incyte’s OPZELURA for Pediatric Atopic Dermatitis (Ages 2–11); Archeus Technologies Receives FDA Clearance for Prostate Cancer Therapy ART-101; Cycle Pharmaceuticals’ HARLIKU Gets First FDA Approval for Alkaptonuria

exploring-life-saving-heart-devices-innovations-transforming-cardiac-care
Articles

Exploring Life-Saving Heart Devices: Innovations Transforming Cardiac Care

pharma-news-for-celltrion-csl-ocugen
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Celltrion Announces FDA Nod for New STEQEYMA Presentation to Broaden Pediatric Use; CSL’s ANDEMBRY Gets FDA Nod as First Factor XIIa Inhibitor for Hereditary Angioedema; Ocugen’s OCU410ST Cleared by FDA to Begin Phase II/III Trial in Stargardt Disease; Milestone Pharmaceuticals Submits FDA Response for CARDAMYST in PSVT; AbbVie’s MAVYRET Approved by FDA as First and Only Therapy for Acute Hepatitis C

business consulting
DelveInsight
Market Research
loader
loader